KR890001567A - Diflunisal and Tromethamine-Containing Compositions - Google Patents

Diflunisal and Tromethamine-Containing Compositions Download PDF

Info

Publication number
KR890001567A
KR890001567A KR1019870006873A KR870006873A KR890001567A KR 890001567 A KR890001567 A KR 890001567A KR 1019870006873 A KR1019870006873 A KR 1019870006873A KR 870006873 A KR870006873 A KR 870006873A KR 890001567 A KR890001567 A KR 890001567A
Authority
KR
South Korea
Prior art keywords
tromethamine
diflunisal
composition
pharmaceutically acceptable
acceptable carrier
Prior art date
Application number
KR1019870006873A
Other languages
Korean (ko)
Inventor
제이.필립스 안토니
Original Assignee
제임스 에프.나우톤
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프.나우톤, 머크 앤드 캄파니 인코포레이티드 filed Critical 제임스 에프.나우톤
Priority to KR1019870006873A priority Critical patent/KR890001567A/en
Publication of KR890001567A publication Critical patent/KR890001567A/en

Links

Abstract

내용 없음No content

Description

디플루니살 및 트로메타민-함유 조성물Diflunisal and Tromethamine-Containing Compositions

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (12)

125 내지 500mg의 디플루니살 및 50 내지 424mg의 트로메타민을 함유하는 조성물.A composition containing 125 to 500 mg of diflunisal and 50 to 424 mg of tromethamine. 제1항에 있어서, 200 내지 500mg의 디플루니살 및 100내지 424mg의 트로메타민을 함유하는 조성물.The composition of claim 1 which contains between 200 and 500 mg of diflunisal and between 100 and 424 mg of tromethamine. 제1항에 있어서, 디플루니살 ; 트로메타민의 중량비가 5:1 내지 5:4인 조성물.The method of claim 1, further comprising diflunisal; Wherein the weight ratio of tromethamine is from 5: 1 to 5: 4. 제1항에 있어서, (a) 500mg의 디플루니살 및 400mg의 트로메타민; (b) 500mg의 디플루니살 및 300mg의 트로메타민 ; (c) 500mg의 디플루니살 및 200mg의 트로메타민; 또는 (d) 500mg의 디플루니살 및 100mg의 트로메타민을 함유하는 조성물.The composition of claim 1 comprising: (a) 500 mg of diflunisal and 400 mg of tromethamine; (b) 500 mg diflunisal and 300 mg tromethamine; (c) 500 mg diflunisal and 200 mg tromethamine; Or (d) a composition containing 500 mg of diflunisal and 100 mg of tromethamine. 제1항의 조성물 및 그의 약제학적으로 허용되는 담체를 함유하는 통증 및 염증 치료용 약제학적 조성물.A pharmaceutical composition for treating pain and inflammation, comprising the composition of claim 1 and a pharmaceutically acceptable carrier thereof. 제5항에 있어서, 200내지 500mg의 디플루니살 ; 100내지 424mg의 트로메타민 ; 및 약제학적으로 허용되는 담체를 함유하는 조성물.The method of claim 5, further comprising 200 to 500 mg of diflunisal; 100-424 mg tromethamine; And a pharmaceutically acceptable carrier. 제5항에 있어서, 다플루니살과 트로메타민의 중량비가 5:1 내지 5:4 인 디플루니살과 트로메타민의 조성물 및 약제학적으로 허용되는 담체를 함유하는 조성물.The composition of claim 5 comprising a composition of diflunisal and tromethamine having a weight ratio of daflunisal and tromethamine of 5: 1 to 5: 4 and a pharmaceutically acceptable carrier. 제5항에 있어서, (a) 500mg의 디플루니살 및 400mg의 트로메타민 ; (b) 500mg의 디플루니살 및 300mg의 트로메타민 ; (c) 500mg의 디플루니살 및 200mg의 트로메타민 ; 또는 (d) 500mg의 디플루니살 및 100mg의 트로메타민의 조성물 ; 및 약제학적으로 허용되는 담체를 함유하는 조성물.The method of claim 5, comprising: (a) 500 mg of diflunisal and 400 mg of tromethamine; (b) 500 mg diflunisal and 300 mg tromethamine; (c) 500 mg diflunisal and 200 mg tromethamine; Or (d) a composition of 500 mg of diflunisal and 100 mg of tromethamine; And a pharmaceutically acceptable carrier. 염증 및 통증의 치료에 유용한 약제를 제조하기 위한 제1항의 조성물의 용도.Use of the composition of claim 1 for the manufacture of a medicament useful for the treatment of inflammation and pain. 제9항에 있어서, 200 내지 500mg의 디플루니살 및 100 내지 424mg의 트로메타민의 조성물을 투여할 경우의 용도.Use according to claim 9 when administering a composition of 200 to 500 mg of diflunisal and 100 to 424 mg of tromethamine. 제9항에 있어서, 조성물이 디플루니살 및 트로메타민을 충량비 5:1 내지 5:4 로 함유할 경우의 용도.The use according to claim 9, wherein the composition contains diflunisal and tromethamine in a filling ratio of 5: 1 to 5: 4. 제9항에 있어서, 조성물이 (a) 500mg의 디플루니살 및 400mg의 트로메타민 ; (b) 500mg의 디플루니살 및 300mg의 트로메타민 ; (c) 500mg의 디플루니살 및 200mg의 트로메타민 ; 또는 (d) 500mg의 디플루니살 및 100mg의 트로메타민을 함유하는 경우의 용도.The composition of claim 9, wherein the composition comprises (a) 500 mg of diflunisal and 400 mg of tromethamine; (b) 500 mg diflunisal and 300 mg tromethamine; (c) 500 mg diflunisal and 200 mg tromethamine; Or (d) use when it contains 500 mg of diflunisal and 100 mg of tromethamine. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870006873A 1987-07-01 1987-07-01 Diflunisal and Tromethamine-Containing Compositions KR890001567A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870006873A KR890001567A (en) 1987-07-01 1987-07-01 Diflunisal and Tromethamine-Containing Compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870006873A KR890001567A (en) 1987-07-01 1987-07-01 Diflunisal and Tromethamine-Containing Compositions

Publications (1)

Publication Number Publication Date
KR890001567A true KR890001567A (en) 1989-03-27

Family

ID=68279678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870006873A KR890001567A (en) 1987-07-01 1987-07-01 Diflunisal and Tromethamine-Containing Compositions

Country Status (1)

Country Link
KR (1) KR890001567A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100576332B1 (en) * 2004-07-16 2006-05-03 강승우 Novel Glyceride Derivatives and Compositions for Pain Relief Comprising the Same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100576332B1 (en) * 2004-07-16 2006-05-03 강승우 Novel Glyceride Derivatives and Compositions for Pain Relief Comprising the Same

Similar Documents

Publication Publication Date Title
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
NO951592D0 (en) Process for the preparation of a transdermal therapeutic system
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
EP0724885A4 (en) Pernasal composition and pernasal preparation containing the same
KR880002515A (en) Fast absorbing and acting sullindac or a mixture of sodium sullindak and base
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
HUP9901360A2 (en) The use of a cimicifuga racemosa extract
KR900007424A (en) Method of using N-acetylglucosamine as a cytoprotective agent and composition thereof
KR890001564A (en) Pharmaceutical dosage unit
KR920702225A (en) Pharmaceutical composition
KR890004705A (en) Antiviral agents
KR910009267A (en) How to Treat Depression
KR880003628A (en) Treated Lip Modifier
KR890001567A (en) Diflunisal and Tromethamine-Containing Compositions
KR880004810A (en) Peptic Ulcer Treatment
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
KR890007728A (en) Painkiller
KR900017599A (en) Pharmaceutical composition for tumor treatment
KR910002792A (en) 1-Substituted-2- (3-amino-1-propynyl) pyrrolidine derivatives, thereby methods for treating central cholinergic dysfunction and pharmaceutical compositions thereof
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
KR870005642A (en) Mixture of Diflunisal and Tromethamine
KR910700263A (en) Medicines containing cyclolinopeptides
KR830009776A (en) Induction of Cell Protection

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination